LLNI Funded Publications
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
Author:Greenfield G
Other Authors: McPherson S, Mills K, McMullin MF,
Last Updated:25/07/2019
Source:PubMed
Original Source:PubMed
Type:Journal Article
DOI:10.1186/s12967-018-1729-7
Journal:Journal of translational medicine
Volume:16
Issue:1
Pages:360
Date: December 2018
Link:https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1729-7
